Crowdonomics
All companies
SEN-JAM PHARMACEUTICAL logo

SEN-JAM PHARMACEUTICAL

Operating

Sen-Jam Pharmaceutical LLC

Alcohol · Lloyd Harbor, DE · Founded 2017

Own a stake for health eauality; affordable and accessible for all

Valuation cap ⓘ
$80.0M
As of Apr 2025 · from Reg CF Offering (2023) · a SAFE/note conversion ceiling, not a priced valuation
Total raised
$3,017,778
Crowd $2.5M · Private $480K · 6 rounds since 2020
Latest share price
$7.35
Reg CF · Common Stock · Oct 2022 offering price

Financials

FY2019–FY2024 · from SEC filings · hover any figure for its source
$0
−$280K
2019
$0
−$337K
2020
$0
−$417K
2021
$0
−$4.0M
2022
$0
−$4.4M
2023
$0
−$4.5M
2024
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2019 reviewed*
FY2020 audited*
FY2021 audited*
FY2022 unaudited
FY2023 audited
FY2024 audited
Income statement
Revenue
$0
$0
$0
$0
$0
$0
Cost of goods sold
$0
$0
$0
$0
$0
$0
Net income
-$280,006
-$336,824
-$417,348
-$3,983,709
-$4,355,706
-$4,475,577
Taxes paid
$860
$0
$0
$0
$0
$0
Balance sheet
Cash
$174
$12,255
$64,694
$181,148
$331,764
$579,282
Accounts receivable
$0
$0
$0
$0
$0
$0
Total assets
$670,364
$505,755
$560,194
$663,018
$950,081
$1,294,445
Short-term debt
$0
$15,292
$47,033
$1,992,097
$1,111,512
$2,762,742
Long-term debt
$0
$417,114
$857,159
$25,000
$1,756,115
$2,239,984
Total liabilities
$0
$432,406
$904,192
$2,017,097
$2,867,627
$5,002,726
Other
Headcount
—
4
5
5
5
5

Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited, as the filing’s own report or certification states it. A dashed pill marked * is inferred instead: the SEC minimum for an offering that size, which the issuer may have exceeded. No pill means we couldn’t tell. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.

Valuation over rounds

Pre-money — the valuation set before each round’s money came in
$25.0M
Valuation cap
$70.0M
pre-money
$80.0M
Valuation cap
Reg CF · Note · Dec 2021
Reg CF · Common · Oct 2022
Reg CF · Note · Jun 2023

Blue bars are the pre-money valuation the company stated for a priced round. Dashed amber bars are a SAFE or convertible note's valuation cap — the most it converts at, not what the company is worth, so don't compare them with the other bars.

Cap table

Share counts as of Dec 31, 2023
ClassOutstandingVotes / shareShare of totalLast price
Common Stock9,571,094—100.0%$7.35Oct 2022

Shares outstanding over timein today's share terms

9.6M4.8M0
Dec 2022Dec 2023
Common StockRound opened

Sold to the crowd

From the company's SEC filings: share counts per class, each class's voting and conversion terms, and the holders of 20% or more that Form C requires (officers and 10%+ holders on Form 1-A). Filings name only large holders, so most owners — including crowd investors — are not listed, and a holder's percentage may be of its own class rather than of the whole company. Prices and crowd share counts are in today's share terms — adjusted for splits and conversions since they were sold. Hover a figure for its filing.

Fundraising history

Raised $0 / $3.3M
Raised $1.5M / $5MInvestors 535Valuation cap $80M
Raised $295KInvestors 6
Raised $57.2K / $4MInvestors 83Post-money $70.3M
Raised $1M / $1.1MInvestors 384Valuation cap $25M
Raised $185KInvestors 5

Team

9 people
Jacqueline M. IversenFounder
Chief Clinical Officer, Co-Founder & Secretary

Jackie has extensive knowledge + capabilities in a multitude of clinical settings. Her expertise involves providing clinical pain education + having completed a research fellowship in pharmacokinetics + pain at Memorial Sloan Kettering Cancer Center.

James IversenFounder
CEO, Co-Founder & Director

Executive with a consistent track record of designing + executing business strategies that deliver rapid growth in sales, profits, market share + customer satisfaction. Client remits include start-ups to late stage, often resulting in M&A transaction

Jim IversenFounder
Co-Founder, CEO
Jacqueline Iversen
Chief Clinical Officer
Christine Leonard
Head of Strategic Communications

Christine is a highly respected and award-winning marcom strategist with passion for brands that aim to improve lives. She has led marketing, consumer insight mining and communications development for world class healthcare companies big and small. She was involved with launching the global Blockbuster brand Dupixient and has a keen understanding of driving success in commerce with both healthcare professionals and consumers across many inflammatory brands.

Neal Zahn
Director of Global Licensing

Wildly successful and seasoned executive in the manufacturing, operations and pharmaceutical industries. Strong bench of skills in the business development space and has fine tuned his legendary resourcefulness in building long lasting, high impact strategic alliances. Charming and unflappable, bringing optimism and pragmatism to the global stage.

Tom Dahl
Head of Product Development and Regulatory Affairs

Accomplished biotech/ pharmaceutical executive with deep expertise in early stage ventures, including technical analysis of products and technologies, business strategy and operations, development, clinical trial design and interpretation. Tenacious and well connected, helping to drive successful outcomes in both the clinical and regulatory arenas.

Dr. Frank Farraye
Scientific Advisor

Dr. Farraye is a Senior Associate Consultant in the Section of Gastroenterology and Hepatology and Professor of Medicine at the Mayo Clinic in Jacksonville, Florida where he directs the Inflammatory Bowel Disease Center. Prior to relocating to Mayo in 2019, he was Clinical Director in the Section of Gastroenterology and the Inflammatory Bowel Disease Center at Boston Medical Center and Professor of Medicine at the Boston University School of Medicine. Dr. Farraye earned his medical doctorate from the Albert Einstein College of Medicine in New York and his master's degree in Epidemiology from the Harvard School of Public Health.

Alexander Wissner-Gross
Advisor

Dr. Alexander D. Wissner-Gross is an award-winning scientist, inventor, entrepreneur, and angel investor. He serves as President and Chief Scientist of Gemedy and holds academic appointments at the Harvard Institute for Applied Computational Science, the Harvard Innovation Lab, and the MIT Media Lab. He has received 123 major distinctions, authored 18 publications, been granted 23 issued, pending, and provisional patents, and founded, managed, and advised 7 technology companies, 3 of which have been acquired. A popular TED speaker, his talks have been viewed almost 2 million times and translated into 27 languages. His work has also been featured in more than 180 press outlets worldwide including The New York Times, CNN, USA Today, the Wall Street Journal, and BusinessWeek.

Names and titles as disclosed on StartEngine, SEC Form C. Bios and photos come from the platform campaign page and may be out of date.

Reg CF annual-report compliance

Not required3+ reports filed & assets ≤ $10M

Filed 3 of 5 annual reports (FY2021–FY2025)

535 investors
holder-count proxy

Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.

  • Form CJun 20, 20250001670254-25-000661
    EDGAR
  • Form C-ARApr 24, 20250001670254-25-000415
    EDGAR
  • Form C/AOct 3, 20240001670254-24-000978
    EDGAR
  • Form D/AJul 25, 20240000929638-24-002581
    EDGAR
  • Form C/AApr 29, 20240001670254-24-000478
    EDGAR
  • Form C-ARApr 26, 20240001670254-24-000459
    EDGAR
  • Form C/ANov 20, 20230001670254-23-001061
    EDGAR
  • Form C/AOct 13, 20230001670254-23-000957
    EDGAR
Source: ManualCIK 0001802249DEShare price $7.35

About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.